Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
US10617673B2 · kind B2 · utility
0Cited by
9References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 29, 2018 |
| Grant date | Apr 14, 2020 |
| Priority date | — |
| Expiry date | May 29, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D231/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.